News Daily News Little Pre- and Postmarket Testing for Most Recalled CV Devices Michael O'Riordan September 16, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Daily News FDA Approves First Transcatheter Tricuspid Valve Replacement Device L.A. McKeown February 02, 2024
News Daily News Symplicity Spyral Approved: FDA Clears Second Renal Denervation System Todd Neale November 20, 2023
News Daily News FDA Grants Tirzepatide a New Indication for Obesity Management L.A. McKeown November 08, 2023
News Daily News FDA Approves Paradise Renal Denervation System: What Comes Next? Todd Neale November 08, 2023
News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021
News Daily News FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon L.A. McKeown February 18, 2021
News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020
News Daily News FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention Shelley Wood June 01, 2020
News Daily News FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl Michael O'Riordan November 14, 2019
News Daily News Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease L.A. McKeown May 06, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2019 Caitlin E. Cox January 31, 2019
News Daily News CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence Caitlin E. Cox September 05, 2018
News Daily News FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke Yael L. Maxwell October 28, 2016